Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02492815 · ClinicalTrials.gov registry record
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,773
- Enrollment target
NCT02492815 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,773 participants.
The verdict
NCT02492815 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,773 participants
- Enrollment target
Study Summary
Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,773 participants |
| Start Date | 2013-10-31 |
| Est. Completion | 2016-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02492815
The ClinicalTrials.gov registry entry for NCT02492815 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,773 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02492815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02492815 about?
NCT02492815 is a clinical study titled "PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma". Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.
What is the current status of trial NCT02492815?
This trial is currently completed. The enrollment target is 1,773 participants. The study started on 2013-10-31. Estimated completion is 2016-04-30.
Who is sponsoring clinical trial NCT02492815?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.